LA JOLLA, Calif., April 25, 2017 /PRNewswire/ — This April 2017, millions of people around the world will recognize Parkinson’s Awareness Month. Parkinson’s disease is a progressive neurological disorder that affects nearly one million people in the US. Although promising research is being conducted, there is currently no cure for or definitive cause of Parkinson’s disease.

StemGenex Medical Group, an organization committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells, noted that Parkinson’s disease is the second most treated condition at its AAAHC Accredited Surgical Center. The organization is a sponsor of the annual golf tournament Birdies Fore Parkinson’s Research, where the money raised is donated to the Michael J. Fox Foundation. 

According to the Parkinson’s Association, approximately 60,000 Americans are diagnosed with Parkinson’s disease each year; seven to 10 million people worldwide are estimated to be living with Parkinson’s disease. The Association noted that the incidence of Parkinson’s increases with age, but an estimated four percent of people with Parkinson’s are diagnosed before the age of 50. Unfortunately, the cause of Parkinson’s is unknown and presently, there is no cure.

Rita Alexander, StemGenex Medical Group’s Chief Administrative Officer, commended the Michael J. Fox Foundation for its early role in supporting work in stem cell research for Parkinson’s disease. Since that time, significant other funding resources — at both the state and federal levels — have been unleashed to support the whole field, allowing the Foundation to continue to target strategic funding in other critical areas of developing therapies for Parkinson’s disease.

«Today, new treatments and advances in research are giving new hope to people affected by Parkinson’s disease,» said Alexander. «StemGenex Medical Group provides Parkinson’s stem cell therapy to potentially help those with unmet clinical needs improve their quality of life.» 

She added, «Through a clinical study we have registered through the National Institutes of Health (NIH), stem cell therapy is being evaluated for efficacy in improving the complications in patients through the use of their own stem cells. These procedures may help patients who don’t respond to typical drug treatment, want to reduce their reliance on medication, or are looking to try stem cell therapy before starting drug treatment.»

Tim Freeman, who went through adult stem cell treatment at StemGenex, stated at the Food and Drug Administration (FDA) Hearing held at the NIH in Bethesda, Maryland, that the treatment dramatically improved his quality of life. 

«I was diagnosed with Parkinson’s disease in 2013. Four years later, I turned from the toxicity and side effects of traditional Parkinson’s medications to adult stem cell treatment. What I experienced has restored hope to my life. I am more focused, more social, have better sleeping habits, have resumed my golf play, and, most importantly, suffered no side effects. I was honored to speak before the FDA to encourage them to not stifle the imagination and innovation of those at the forefront of regenerative medicine, which I believe one day will unlock the secrets of the human body’s ability to aid in curing so many diseases.»

Recently, the 21st Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama in December of 2016. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy.

Freeman’s testimonial can be seen at

ABOUT StemGenex Medical Group
StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment, StemGenex sponsors five clinical outcome studies registered with the National Institutes of Health («NIH») for Multiple Sclerosis, Parkinson’s Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease («COPD») and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment

Jamie Schubert, Director of Media & Community Relations
[email protected] 858.242.4243


To view the original version on PR Newswire, visit:

SOURCE StemGenex